Drugs / Curcuma xanthorriza Roxb.
Curcuma xanthorriza Roxb.
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06153134 Comparator | Dec 2023 → Feb 2024 | hyperpigmentation of the skin | Padjadjaran University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curcuma xanthorriza Roxb. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06153134 ↗ |
| Known as | koneng gede | “Curcuma xanthorrhiza Roxb., known locally as temulawak in Indonesia or koneng gede in Sundanese, is a member of the Zingiberaceae family and is native to Indonesia.” NCT06153134 ↗ |
| Known as | temulawak | “Curcuma xanthorrhiza Roxb., known locally as temulawak in Indonesia or koneng gede in Sundanese, is a member of the Zingiberaceae family and is native to Indonesia.” NCT06153134 ↗ |
| Action | Inhibit | “operates by inhibiting the tyrosinase enzyme” NCT06153134 ↗ |
| Route | Topical | “Fifteen patients will apply 10% Curcuma xanthorriza Roxb. cream topically at the half of the face, once daily in night, for 2 months.” NCT06153134 ↗ |